Q1 2026 Viking Therapeutics Inc Earnings Call Transcript
Key Points
- Viking Therapeutics Inc (VKTX) completed enrollment in both the VANQUISH-1 and VANQUISH-2 Phase III trials, indicating strong progress in their clinical programs.
- The company is advancing both injectable and oral formulations of VK2735, providing flexibility and optionality in treatment for obesity.
- Viking Therapeutics Inc (VKTX) has a robust cash position with $603 million in cash, cash equivalents, and short-term investments, ensuring financial stability to reach key milestones.
- The introduction of an auto-injector device in the VANQUISH studies is expected to enhance patient convenience and treatment adherence.
- The company is expanding its team, including the appointment of a Chief Commercial Officer, to prepare for potential commercialization of VK2735.
- Viking Therapeutics Inc (VKTX) reported a significant increase in net loss to $158.3 million for Q1 2026, primarily due to increased research and development expenses.
- The company's cash balance decreased from $706 million at the end of 2025 to $603 million by March 31, 2026, reflecting high cash burn.
- There is uncertainty regarding the expected weight loss efficacy in type 2 diabetic patients compared to non-diabetic obese patients, which could impact trial outcomes.
- The expansion of maintenance dosing cohorts in the ongoing study may lead to increased complexity and potential delays in obtaining results.
- The oral VK2735 program's Phase III initiation has been pushed to the fourth quarter of 2026, indicating potential delays in development timelines.
Welcome to the Viking Therapeutics first quarter 2026 financial results conference call. (Operator Instructions) As a reminder, this conference call is being recorded today, April 29, 2026.
I would now like to turn the conference over to Viking's Manager of Investor Relations, Stephanie Diaz. Thank you, and over to you.
Hello, and thank you all for participating in today's call. Joining me today is Brian Lian, Viking's President and CEO; and Greg Zante, Viking's CFO.
Before we begin, I'd like to caution that comments made during this conference call today, April 29, 2026, will contain forward-looking statements under the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995, including statements about Viking's expectations regarding its development activities, timelines, and milestones. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely and reported results should
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
